Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Nicholas Thatcher; Jerome H. Goldschmidt; Michael Thomas; Michael Schenker; Zhiying Pan; Luis Paz-Ares Rodriguez; Valery Breder; Gyula Ostoros; Vladimir Hanes

doi:10.1158/1078-0432.CCR-18-2702

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Nicholas Thatcher
, Jerome H. Goldschmidt
, Michael Thomas
, Michael Schenker
, Zhiying Pan
, Luis Paz-Ares Rodriguez
, Valery Breder
, Gyula Ostoros
, Vladimir Hanes

The Christie Hospital, Manchester, United Kingdom.
Oncology and Hematology Associates of Southwest Virginia, US Oncology Research, McKesson Specialty Health, Blacksburg, Virginia.
University Hospital Heidelberg
Centrul de Oncologie Sf Nectarie, Craiova, Romania.
Amgen
Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
Department of Clinical Biotechnologies, N. N. Blokhin National Medical Research Center of Oncology, Russia.
Koranyi National Institute for TB and Pulmonology, Budapest, Hungary.

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Cancer Research
Volume	25
Issue number	7
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-2702
State	Published - Jan 7 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1158/1078-0432.CCR-18-2702License: Unspecified

Cite this

Thatcher, N., Goldschmidt, J. H., Thomas, M., Schenker, M., Pan, Z., Rodriguez, L. P.-A., Breder, V., Ostoros, G., & Hanes, V. (2019). Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clinical Cancer Research, 25(7). https://doi.org/10.1158/1078-0432.CCR-18-2702

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. / Thatcher, Nicholas; Goldschmidt, Jerome H.; Thomas, Michael et al.
In: Clinical Cancer Research, Vol. 25, No. 7, 07.01.2019.

Research output: Contribution to journal › Article › peer-review

Thatcher, N, Goldschmidt, JH, Thomas, M, Schenker, M, Pan, Z, Rodriguez, LP-A, Breder, V, Ostoros, G & Hanes, V 2019, 'Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study', Clinical Cancer Research, vol. 25, no. 7. https://doi.org/10.1158/1078-0432.CCR-18-2702

@article{cb764ab1cf3e4fd3a41b9a2293a51486,

title = "Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study",

author = "Nicholas Thatcher and Goldschmidt, \{Jerome H.\} and Michael Thomas and Michael Schenker and Zhiying Pan and Rodriguez, \{Luis Paz-Ares\} and Valery Breder and Gyula Ostoros and Vladimir Hanes",

year = "2019",

month = jan,

day = "7",

doi = "10.1158/1078-0432.CCR-18-2702",

language = "American English",

volume = "25",

journal = "Clinical Cancer Research",

issn = "1557-3265",

publisher = "American Association for Cancer Research",

number = "7",

}

TY - JOUR

T1 - Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

AU - Thatcher, Nicholas

AU - Goldschmidt, Jerome H.

AU - Thomas, Michael

AU - Schenker, Michael

AU - Pan, Zhiying

AU - Rodriguez, Luis Paz-Ares

AU - Breder, Valery

AU - Ostoros, Gyula

AU - Hanes, Vladimir

PY - 2019/1/7

Y1 - 2019/1/7

UR - https://clincancerres.aacrjournals.org/content/clincanres/25/7/2088.full.pdf

U2 - 10.1158/1078-0432.CCR-18-2702

DO - 10.1158/1078-0432.CCR-18-2702

M3 - Article

SN - 1557-3265

VL - 25

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Disciplines

Access to Document

Other files and links

Cite this